Gaurav Kharya
Overview
Explore the profile of Gaurav Kharya including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
142
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Faizan M, Chaudhuri R, Sagar S, Albogami S, Chaudhary N, Azmi I, et al.
Cells
. 2022 Oct;
11(19).
PMID: 36230930
Circulating cell-free mitochondrial DNA (cf-mtDNA) has been found in the plasma of severely ill COVID-19 patients and is now known as a strong predictor of mortality. However, the underlying mechanism...
12.
Thakur P, Gupta P, Bhargava N, Soni R, Gottumukkala N, Goswami S, et al.
Diagnostics (Basel)
. 2022 Jul;
12(7).
PMID: 35885667
Sickle cell disease (SCD) is the most prevalent life-threatening blood monogenic disorder. Currently, there is no cure available, apart from bone marrow transplantation. Early and efficient diagnosis of SCD is...
13.
Danewa A, Kalra M, Sachdeva A, Sachdeva P, Bansal D, Bhat S, et al.
Indian Pediatr
. 2022 Feb;
59(6):467-475.
PMID: 35105820
Justification: In India, there is a lack of uniformity of treatment strategies for aplastic anemia (AA), and many children are managed only with supportive care due to non-availability of hematopoietic...
14.
Raj R, Aboobacker F, Yadav S, Uppuluri R, Bhat S, Choudhry D, et al.
Front Immunol
. 2021 Jan;
11:606930.
PMID: 33488609
Background: Hematopoietic stem cell transplantation (HSCT) is the curative option for many primary immune deficiency disorders (PID). In the last 5 years, increased awareness, availability of diagnostics based on flow...
15.
Kharya G, Bakane A, Rauthan A
Pediatr Blood Cancer
. 2021 Jan;
68(4):e28909.
PMID: 33470527
Hematopoietic stem cell transplant (HSCT) is currently the only curative option for thalassemia major (TM) and sickle cell disease (SCD). We report our experience of using pretransplant immune suppression (PTIS),...
16.
Bakane A, Rauthan A, Madasu A, Kharya G
Pediatr Blood Cancer
. 2020 Dec;
68(4):e28792.
PMID: 33283958
No abstract available.
17.
Kharya G, Bakane A, Agarwal S, Rauthan A
Bone Marrow Transplant
. 2020 Sep;
56(2):492-504.
PMID: 32929175
Allogenic hematopoietic stem cell transplant is the only curative option for symptomatic sickle cell disease (SCD). HLA haploidentical related donor transplants are associated with high graft failure rates. We conceptualized...
18.
Setia R, Arora S, Handoo A, Dadu T, Choudhary D, Sharma S, et al.
Transfus Apher Sci
. 2017 May;
56(3):439-444.
PMID: 28528807
Introduction: Most common source of stem cell graft for both autologous and allogenic haematopoietic transplants are peripheral blood haematopoietic progenitor stem cells. Adequate collection of the CD34+ cells and safety...
19.
Sharma S, Choudhary D, Kaul E, Kharya G, Khandelwal V, Kothari S, et al.
Indian J Hematol Blood Transfus
. 2016 Jul;
32(Suppl 1):205-7.
PMID: 27408392
No abstract available.
20.
Sharma S, Choudhary D, Handoo A, Dhamija G, Kharya G, Khandelwal V, et al.
Mediterr J Hematol Infect Dis
. 2015 May;
7(1):e2015036.
PMID: 25960864
No abstract available.